1 Patisaul HB, Jefferson W (2010) The pros and cons of phytoestrogens. Front Neuroendocrinol 31: 400-19.
2 Barnes S (2010) The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat Res Biol 8: 89-98.
3 Nestel PJ, Pomeroy S, Kay S, Behrsing J, Cameron JD, et al. (1999) Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 84: 895-8.
4 Cederroth CR, Zimmermann C, Nef S (2012) Soy, phytoestrogens and their impact on reproductive health. Mol Cell Endocrinol 355: 192-200.
5 Baber R (2010) Phytoestrogens and post reproductive health. Maturitas 66: 344-9.
6 Gencel VB, Benjamin MM, Bahou SN, Khalil RA (2012) Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease. Mini Rev Med Chem 12: 149-74.
7Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M (2012) Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause 19: 776-90.
8 Gold EB, Leung K, Crawford SL, Huang MH, Waetjen LE, et al. (2013) Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms: results from the Study of Women's Health Across the Nation. Menopause 20: 305-14.
9Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, et al. (2013) Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 12: CD001395.
10Krebs EE, Ensrud KE, MacDonald R, Wilt TJ (2004) Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 104: 824-36.
11Cheema D, Coomarasamy A, El-Toukhy T (2007) Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet 276: 463-9.
12 Al-Azzawi F, Wahab M (2010) Effectiveness of phytoestrogens in climacteric medicine. Ann N Y Acad Sci 1205: 262-7.
13 Villaseca P (2012) Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric 15: 115-24.
14Speroff L (2005) Alternative therapies for postmenopausal women. Int J Fertil Womens Med 50: 101-14.
15Poluzzi E, Piccinni C, Raschi E, Rampa A, Recanatini M, et al. (2014) Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective. Curr Med Chem 21: 417-36.
16 de Villiers TJ, Bagratee JS, Dalmeyer JP, Davey MR, Davis CP, et al. (2007) South African Menopause Society Council revised consensus position statement on menopausal hormone therapy. S Afr Med J 97: 354-7.
17Sirtori CR, Arnoldi A, Johnson SK (2005) Phytoestrogens: end of a tale? Ann Med 37: 423-38.
18Davis SR (2001) Phytoestrogen therapy for menopausal symptoms? BMJ 323: 354-5.
19 Coxam V (2008) Phyto-oestrogens and bone health. Proc Nutr Soc 67: 184-95.
20 Lagari VS, Levis S (2013) Phytoestrogens in the prevention of postmenopausal bone loss. J Clin Densitom 16: 445-9.
21Castelo-Branco C, Soveral I (2013) Phytoestrogens and bone health at different reproductive stages. Gynecol Endocrinol 29: 735-43.
22 This P, de Cremoux P, Leclercq G, Jacquot Y (2011) A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas 70: 222-6.
23Haimov-Kochman R, Brzezinski A, Hochner-Celnikier D (2008) Herbal remedies for menopausal symptoms: are we cautious enough? Eur J Contracept Reprod Health Care 13: 133-7.
24Wilson S, Blaschek K, de Mejia E (2005) Allergenic proteins in soybean: processing and reduction of P34 allergenicity. Nutr Rev 63: 47-58.
25Saayman BD (2011) The use of alternative lipid emulsions in paediatric and neonatal parenteral nutrition. S Afr J Clin Nutr 24: S32-4.
26Leclercq G, de Cremoux P, This P, Jacquot Y (2011) Lack of sufficient information on the specificity and selectivity of commercial phytoestrogens preparations for therapeutic purposes. Maturitas 68: 56-64.
27 Usui T (2006) Pharmaceutical prospects of phytoestrogens. Endocr J 53: 7-20.
28Setchell KD, Clerici C (2010) Equol: history, chemistry, and formation. J Nutr 140: 1355-62S.
29Adgent MA, Daniels JL, Edwards LJ, Siega-Riz AM, Rogan WJ (2011) Early-life soy exposure and gender-role play behavior in children. Environ Health Perspect 119: 1811-6.
30 Martinez J, Lewi JE (2008) An unusual case of gynecomastia associated with soy product consumption. Endocr Pract 14: 415-8.
31 Thelen P, Wuttke W, Seidlová-Wuttke D (2014) Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer. J Steroid Biochem Mol Biol 139: 290-3.
32Jefferson WN, Williams CJ (2011) Circulating levels of genistein in the neonate, apart from dose and route, predict future adverse female reproductive outcomes. Reprod Toxicol 31: 272-9.
33Whitten PL, Lewis C, Russell E, Naftolin F (1995) Potential adverse effects of phytoestrogens. J Nutr 125: 771-6S.
34Seliukova NIu, Karpenko NO, Korenieva IeM, Somova OV, Smolienko NP, et al. (2014) The impact of male phytoestrogenization on the somato-sexual development and fertility of the offsprings in rats. Fiziol Zh 60: 82-7.
35Latendresse JR, Bucci TJ, Olson G, Mellick P, Weis CC, et al. (2009) Genistein and ethinyl estradiol dietary exposure in multigenerational and chronic studies induce similar proliferative lesions in mammary gland of male Sprague-Dawley rats. Reprod Toxicol 28: 342-53.
36Messina M, Melby MK, Kronenberg F, Kurzer MS, Taku K (2013) Letter to the editor. Menopause 20: 359-61.
37 Sirotkin AV, Harrath AH (2014) Phytoestrogens and their effects. Eur J Pharmacol 741: 230-6.
38Jargin SV, Wilson DW (2014) Some pitfalls in testing antiatherogenic agents in cell cultures. World Heart J 6 149-55.
39 Nikitina NA, Sobenin IA, Myasoedova VA, Korennaya VV, Mel'nichenko AA, et al. (2006) Antiatherogenic effect of grape flavonoids in an ex vivo model. Bull Exp Biol Med 141: 712-5.
40Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, et al. (2013) Anti-atherosclerotic therapy based on botanicals. Recent Pat Cardiovasc Drug Discov 8: 56-66.
41 Korennaya VV, Myasoedova VA, Nikitina NA, Sobenin IA, Orekhov AN (2006) Bioflavonoid-rich botanicals reduce blood serum atherogenicity in perimenopausal women. Abstracts of the XIV International Symposium on Atherosclerosis (ISA), 18-22 June 2006, Rome, Italy. Atheroscler Suppl 7: 444.
42Ryong LH, Tertov VV, Vasil'ev AV, Tutel'yan VA, Orekhov AN (1989) Antiatherogenic and antiatherosclerotic effects of mushroom extracts revealed in human aortic intima cell culture. Drug Dev Res 17:109-17.
43 Orekhov AN, Baldenkov GN, Tertov VV, Ryong LH, Kozlov SG, et al. (1988) Cardiovascular drugs and atherosclerosis: Effects of calcium antagonists, betablockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol 12 Suppl 6: S66-8.
44Orekhov AN, Melnichenko AA, Sobenin IA (2014) Approach to reduction of blood atherogenicity. Oxid Med Cell Longev 2014: 738679.
45 Orekhov AN, Pivovarova EM, Sobenin IA, Yakushkin VV, Tertov VV (1992) Use of cell culture for optimisation of direct antiatherogenic therapy with verapamil. Drugs 1: 105-10.
46Marais AD (2004) Familial hypercholesterolaemia. Clin Biochem Rev 25: 49-68.
47Goldstein JL, Brown MS (2009) The LDL receptor. Arterioscler Thromb Vasc Biol 29: 431-8.
48 Goldstein JL, Brown MS (1984) Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 25: 1450-61.
49Ricciarelli R, Zingg JM, Azzi A (2000) Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 102: 82-7.
50 Llorente-Cortés V, Badimon L (2005) LDL receptor-related protein and the vascular wall: implications for atherothrombosis. Arterioscler Thromb Vasc Biol 25: 497-504.
51Gong Q, Pitas RE (1995) Synergistic effects of growth factors on the regulation of smooth muscle cell scavenger receptor activity. J Biol Chem 270: 21672-8.
52 Pirillo A, Norata GD, Catapano AL (2013) LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013: 152786.
53 Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P (2013) LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol. Life Sci 70: 2859-72.
54 Chazov EI, Tertov VV, Orekhov AN, Lyakishev AA, Perova NV, et al. (1986) Atherogenicity of blood serum from patients with coronary heart disease. Lancet 2: 595-8.